المؤلفون: Martino, S. A, Cauley, J. A. B, Barrett Connor, E. C, Powles, T. J. D, Mershon, J. E, Disch, D. E, Secrest, R. J. E, Cummings, S. R. F, Mautalen, C. A. G, Zanchetta, J. R. H, Hooper, M. J. I, K. W. J, Ng, Prince, R. L. K, Nicholson, G. L, Roberts, A. P. M, Seeman, E. N, Williamson, M. O, Boschitsch, E. P, Leb, G. Q, Body, J. J. R, Devogelaer, J. P. S, Geusens, P. T, Kaufman, J. M. u, Peretz, A. V, Adachi, J. W, Bensen, W. X, Brown, J. P. Y, Cheung, A. Z, Chik, C. Aa, Gee, S. Ab, Hanley, D. Ac, Hawker, G. A. Ad, Hodsman, A. B. Ae, Joyce, C. Af, Monchesky, T. C. Ag, Olszynski, W. P. Ah, Roe, B. Ai, Senikas, V. Aj, Seminoski, K. Ak, Wall, J. Ab, Stepan, J. Al, Hyldstrup, L. Am, Langdahl, B. An, Sorensen, T. H. Ao, Alhava, E. Ap, Kormano, M. Aq, Salmela, P. Ar, Salmi, J. As, Valimaki, M. At, Audran, M. Au, Briancon, D. Av, Delmas, P. Aw, Fardellone, P. Ax, Ribot, C. Ay, De Vernejoul, M. C. Az, Balogh, A. Ba, Julesz, J. Bb, Szuecs, J. Bc, Karsik, A. Bd, Fiore, C. Be, Genazzani, A. R. Bf, Gennari, C. Bg, Isaia, Giovanni Carlo, Melis, G. B. Bi, Nuti, R. Bg, Oriente, P. Bj, Passeri, M. Bk, Sartori, L. Bl, Corea Rotter, R. Bm, Gonzalez, S. Bn, Murillo, A. Bo, Jonker, J. J. Bp, Lips, P. Bq, Mulder, H. Br, Pols, H. A. Bs, Halse, J. I. Bt, Hoiseth, A. Bu, Jorde, R. Bv, Olford, E. S. Bw, Skag, A. Bw, Stakkestad, J. A. Bx, Wist, E. By, Badurski, J. E. Bz, Hoszowski, K. Ca, Ogonowski, J. Cc, Bose, K. Cb, Lee, K. O. Cb, Dzurik, R. Cd, Kocijancic, A. Ce, Cannata Andia, J. B. Cf, Collado, R. C. Cg, Carranza, F. H. Ch, Diez Perez, A. Cf, Escobar Jimenez, F. Ci, Minguella, J. F. Cj, Solan, X. N. Cf, Torres, M. M. Cj, Larsson, K. Ck, Malströem, D. Cl

المصدر: Journal of the National Cancer Institute. 96(23)

مصطلحات موضوعية: Selective Estrogen Receptor Modulators, Cancer Research, medicine.medical_specialty, Antineoplastic Agents, Hormonal, Breast Neoplasms, Placebo, Drug Administration Schedule, law.invention, Breast cancer, Randomized controlled trial, Double-Blind Method, Estrogen Receptor Modulators, law, Internal medicine, medicine, Humans, Raloxifene, Osteoporosis, Postmenopausal, Aged, Gynecology, business.industry, Raloxifene Hydrochloride, Incidence, Patient Selection, Lasofoxifene, Middle Aged, medicine.disease, United States, Treatment Outcome, Oncology, Selective estrogen receptor modulator, Female, business, Tamoxifen, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eead0c61e3c5f10b05d2641d019360cc
https://pubmed.ncbi.nlm.nih.gov/15812082